Geron Corporation (GERN) Q2 2025 Earnings Call Transcript

Geron Corporation reported Q2 2025 RYTELO net revenues of $49 million, a 24% quarter-over-quarter increase, driven by a 17% rise in demand from new patient starts and expanded utilization across 1,000 sites of care. The company highlighted that approximately 30% of new patient starts were in earlier lines of therapy, while payer access for RYTELO reached 90% of U.S. covered lives. To sustain growth, Geron expanded its commercial sales force by over 20% and doubled its medical affairs organization, with impact anticipated by year-end. Concurrently, Harout Semerjian was appointed as the new President and CEO, and the Phase III IMpactMF trial for myelofibrosis is 95% enrolled, expected to complete by year-end 2025. Geron concluded Q2 with $433 million in cash, supporting ongoing U.S. commercialization and planned 2026 EU launches.

Analysis

Geron Corporation's Q2 2025 results demonstrate positive momentum for its RYTELO launch, with net revenues hitting $49 million, a 24% increase over the prior quarter, driven by a 17% rise in underlying demand. This performance reflects early success from a strategic pivot implemented in March, which prioritizes increased brand awareness and physician education. Key commercial metrics support this trend, with utilization expanding to approximately 1,000 sites of care and a robust two-thirds reorder rate from existing accounts. Payer access is strong at 90% of U.S. covered lives, de-risking reimbursement hurdles. While approximately 30% of new patients are now in earlier first and second-line settings, the bulk of usage remains in third-line plus. The company's substantial investment in expanding its commercial and medical affairs teams by over 20% and 100%, respectively, is a forward-looking initiative aimed at accelerating this shift to earlier lines, with impacts anticipated by year-end. The appointment of new CEO Harout Semerjian provides leadership stability, while the IMpactMF Phase III trial's expected enrollment completion by year-end 2025 sets the stage for a key interim data readout in H2 2026, representing a significant future catalyst. The company's cash position of $433 million appears adequate to fund these growth initiatives based on its current expense guidance.

Key Decisions for Investors

• Investors should monitor RYTELO's demand trends and the reported mix of new patient starts in subsequent quarters to validate that the recent expansion of the commercial and medical teams is successfully accelerating adoption in earlier lines of therapy, which is critical for achieving peak sales estimates.
• The IMpactMF Phase III trial in myelofibrosis represents a significant long-term value driver; while interim data is not expected until the second half of 2026, the completion of enrollment by year-end 2025 is a crucial near-term milestone to watch.
• With operating expenses guided at $270-$285 million for the year, the trajectory of RYTELO's revenue growth is paramount, and continued acceleration is needed to demonstrate a clear path to self-sustainability and reduce reliance on existing cash reserves.
• The new CEO's execution of the commercial strategy is a key variable, and investors should watch for commentary on further strategic refinements or capital allocation priorities in the coming quarters.